Perrigo Company plc (NYSE:PRGO) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System trimmed its holdings in shares of Perrigo Company plc (NYSE:PRGO) by 3.1% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 179,376 shares of the company’s stock after selling 5,791 shares during the quarter. New York State Teachers Retirement System’s holdings in Perrigo were worth $5,772,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Dark Forest Capital Management LP acquired a new position in Perrigo during the first quarter valued at approximately $31,000. Ronald Blue Trust Inc. raised its stake in shares of Perrigo by 132.3% during the third quarter. Ronald Blue Trust Inc. now owns 1,157 shares of the company’s stock valued at $39,000 after purchasing an additional 659 shares during the period. Blue Trust Inc. raised its stake in shares of Perrigo by 34.5% during the fourth quarter. Blue Trust Inc. now owns 1,556 shares of the company’s stock valued at $50,000 after purchasing an additional 399 shares during the period. NewEdge Advisors LLC raised its stake in shares of Perrigo by 345.5% during the first quarter. NewEdge Advisors LLC now owns 1,430 shares of the company’s stock valued at $51,000 after purchasing an additional 1,109 shares during the period. Finally, Fifth Third Bancorp raised its stake in shares of Perrigo by 39.5% during the third quarter. Fifth Third Bancorp now owns 1,714 shares of the company’s stock valued at $55,000 after purchasing an additional 485 shares during the period. 95.91% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Perrigo news, EVP Robert Willis acquired 6,000 shares of the firm’s stock in a transaction on Thursday, February 29th. The stock was purchased at an average price of $25.87 per share, with a total value of $155,220.00. Following the completion of the acquisition, the executive vice president now directly owns 25,105 shares in the company, valued at approximately $649,466.35. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Perrigo news, EVP Alison Ives acquired 2,490 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was purchased at an average price of $27.26 per share, with a total value of $67,877.40. Following the completion of the acquisition, the executive vice president now directly owns 16,122 shares in the company, valued at approximately $439,485.72. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Robert Willis acquired 6,000 shares of the firm’s stock in a transaction on Thursday, February 29th. The stock was acquired at an average cost of $25.87 per share, with a total value of $155,220.00. Following the acquisition, the executive vice president now owns 25,105 shares of the company’s stock, valued at $649,466.35. The disclosure for this purchase can be found here. Insiders acquired a total of 17,990 shares of company stock valued at $475,227 over the last 90 days. 0.70% of the stock is owned by company insiders.

Analyst Ratings Changes

PRGO has been the topic of a number of analyst reports. StockNews.com upgraded shares of Perrigo from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Canaccord Genuity Group reiterated a “buy” rating and set a $42.00 price objective on shares of Perrigo in a research note on Friday. Piper Sandler lifted their price objective on shares of Perrigo from $35.00 to $39.00 and gave the company an “overweight” rating in a research note on Monday, April 8th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Perrigo from $48.00 to $41.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 28th.

Perrigo Trading Down 3.1 %

Shares of NYSE:PRGO opened at $30.33 on Friday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.07 and a current ratio of 1.79. The company has a fifty day simple moving average of $30.80 and a 200 day simple moving average of $30.83. Perrigo Company plc has a 12-month low of $25.77 and a 12-month high of $40.28.

Perrigo (NYSE:PRGO) last issued its quarterly earnings results on Tuesday, February 27th. The company reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.17 billion. Perrigo had a negative net margin of 0.27% and a positive return on equity of 7.34%. The business’s revenue was up .1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.75 earnings per share. Analysts expect that Perrigo Company plc will post 2.55 EPS for the current year.

Perrigo Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 26th. Shareholders of record on Friday, March 8th were issued a $0.276 dividend. This represents a $1.10 dividend on an annualized basis and a yield of 3.64%. The ex-dividend date of this dividend was Thursday, March 7th. This is an increase from Perrigo’s previous quarterly dividend of $0.27. Perrigo’s payout ratio is currently -1,100.00%.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.